CXCR4 peptide-based fluorescence endoscopy in a mouse model of Barrett's esophagus.
Détails
Télécharger: 35006394_BIB_B9E2214CAD9F.pdf (2399.33 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_B9E2214CAD9F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
CXCR4 peptide-based fluorescence endoscopy in a mouse model of Barrett's esophagus.
Périodique
EJNMMI research
ISSN
2191-219X (Print)
ISSN-L
2191-219X
Statut éditorial
Publié
Date de publication
10/01/2022
Peer-reviewed
Oui
Volume
12
Numéro
1
Pages
2
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
Near-infrared (NIR) fluorescence imaging has been emerging as a promising strategy to overcome the high number of early esophageal adenocarcinomas missed by white light endoscopy and random biopsy collection. We performed a preclinical assessment of fluorescence imaging and endoscopy using a novel CXCR4-targeted fluorescent peptide ligand in the L2-IL1B mouse model of Barrett's esophagus.
Six L2-IL1B mice with advanced stage of disease (12-16 months old) were injected with the CXCR4-targeted, Sulfo-Cy5-labeled peptide (MK007), and ex vivo wide-field imaging of the whole stomach was performed 4 h after injection. Before ex vivo imaging, fluorescence endoscopy was performed in three L2-IL1B mice (12-14 months old) by a novel imaging system with two L2-IL1B mice used as negative controls.
Ex vivo imaging and endoscopy in L2-IL1B mice showed that the CXCR4-targeted MK007 accumulated mostly in the dysplastic lesions with a mean target-to-background ratio > 2. The detection of the Sulfo-Cy5 signal in dysplastic lesions and its co-localization with CXCR4 stained cells by confocal microscopy further confirmed the imaging results.
This preliminary preclinical study shows that CXCR4-targeted fluorescence endoscopy using MK007 can detect dysplastic lesions in a mouse model of Barrett's esophagus. Further investigations are needed to assess its use in the clinical setting.
Six L2-IL1B mice with advanced stage of disease (12-16 months old) were injected with the CXCR4-targeted, Sulfo-Cy5-labeled peptide (MK007), and ex vivo wide-field imaging of the whole stomach was performed 4 h after injection. Before ex vivo imaging, fluorescence endoscopy was performed in three L2-IL1B mice (12-14 months old) by a novel imaging system with two L2-IL1B mice used as negative controls.
Ex vivo imaging and endoscopy in L2-IL1B mice showed that the CXCR4-targeted MK007 accumulated mostly in the dysplastic lesions with a mean target-to-background ratio > 2. The detection of the Sulfo-Cy5 signal in dysplastic lesions and its co-localization with CXCR4 stained cells by confocal microscopy further confirmed the imaging results.
This preliminary preclinical study shows that CXCR4-targeted fluorescence endoscopy using MK007 can detect dysplastic lesions in a mouse model of Barrett's esophagus. Further investigations are needed to assess its use in the clinical setting.
Mots-clé
Animal models, Barrett’s esophagus, CXCR4, Dysplasia, Endoscopy, Esophageal cancer, Fluorescence imaging, Molecular imaging, Peptide
Pubmed
Web of science
Open Access
Oui
Création de la notice
17/01/2022 11:08
Dernière modification de la notice
23/11/2022 7:14